These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
716 related articles for article (PubMed ID: 7585538)
1. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Salgaller ML; Afshar A; Marincola FM; Rivoltini L; Kawakami Y; Rosenberg SA Cancer Res; 1995 Nov; 55(21):4972-9. PubMed ID: 7585538 [TBL] [Abstract][Full Text] [Related]
2. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. Parkhurst MR; Salgaller ML; Southwood S; Robbins PF; Sette A; Rosenberg SA; Kawakami Y J Immunol; 1996 Sep; 157(6):2539-48. PubMed ID: 8805655 [TBL] [Abstract][Full Text] [Related]
3. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Salgaller ML; Marincola FM; Cormier JN; Rosenberg SA Cancer Res; 1996 Oct; 56(20):4749-57. PubMed ID: 8840994 [TBL] [Abstract][Full Text] [Related]
4. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296 [TBL] [Abstract][Full Text] [Related]
5. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734 [TBL] [Abstract][Full Text] [Related]
6. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. Kawakami Y; Eliyahu S; Jennings C; Sakaguchi K; Kang X; Southwood S; Robbins PF; Sette A; Appella E; Rosenberg SA J Immunol; 1995 Apr; 154(8):3961-8. PubMed ID: 7706734 [TBL] [Abstract][Full Text] [Related]
7. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients. Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871 [TBL] [Abstract][Full Text] [Related]
8. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823 [TBL] [Abstract][Full Text] [Related]
9. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL. Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015 [TBL] [Abstract][Full Text] [Related]
10. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes. Dudley ME; Ngo LT; Westwood J; Wunderlich JR; Rosenberg SA Cancer J; 2000; 6(2):69-77. PubMed ID: 11069222 [TBL] [Abstract][Full Text] [Related]
11. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100. Skipper JC; Kittlesen DJ; Hendrickson RC; Deacon DD; Harthun NL; Wagner SN; Hunt DF; Engelhard VH; Slingluff CL J Immunol; 1996 Dec; 157(11):5027-33. PubMed ID: 8943411 [TBL] [Abstract][Full Text] [Related]
12. Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity. Abdel-Wahab Z; DeMatos P; Hester D; Dong XD; Seigler HF Cell Immunol; 1998 May; 186(1):63-74. PubMed ID: 9637766 [TBL] [Abstract][Full Text] [Related]
13. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis. Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095 [TBL] [Abstract][Full Text] [Related]
14. Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens. Castelli C; Tarsini P; Mazzocchi A; Rini F; Rivoltini L; Ravagnani F; Gallino F; Belli F; Parmiani G J Immunol; 1999 Feb; 162(3):1739-48. PubMed ID: 9973437 [TBL] [Abstract][Full Text] [Related]
15. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. Rivoltini L; Kawakami Y; Sakaguchi K; Southwood S; Sette A; Robbins PF; Marincola FM; Salgaller ML; Yannelli JR; Appella E J Immunol; 1995 Mar; 154(5):2257-65. PubMed ID: 7868898 [TBL] [Abstract][Full Text] [Related]
16. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Bakker AB; Marland G; de Boer AJ; Huijbens RJ; Danen EH; Adema GJ; Figdor CG Cancer Res; 1995 Nov; 55(22):5330-4. PubMed ID: 7585596 [TBL] [Abstract][Full Text] [Related]
17. Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope-major histocompatibility complex class I fusion proteins. Kang X; Robbins PF; Fitzgerald EB; Wang R; Rosenberg SA; Kawakami Y Cancer Res; 1997 Jan; 57(2):202-5. PubMed ID: 9000554 [TBL] [Abstract][Full Text] [Related]
18. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy. Rivoltini L; Loftus DJ; Barracchini K; Arienti F; Mazzocchi A; Biddison WE; Salgaller ML; Appella E; Parmiani G; Marincola FM J Immunol; 1996 May; 156(10):3882-91. PubMed ID: 8621927 [TBL] [Abstract][Full Text] [Related]
19. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition. Stevens EJ; Jacknin L; Robbins PF; Kawakami Y; el Gamil M; Rosenberg SA; Yannelli JR J Immunol; 1995 Jan; 154(2):762-71. PubMed ID: 7814882 [TBL] [Abstract][Full Text] [Related]